562 related articles for article (PubMed ID: 29555460)
1. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
2. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
3. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
4. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
7. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
[TBL] [Abstract][Full Text] [Related]
8. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
10. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
11. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
12. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
[TBL] [Abstract][Full Text] [Related]
13. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
[No Abstract] [Full Text] [Related]
14. Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy.
Ye PJ; Huang C; Yang S; Gao P; Li ZP; Tang SY; Xiang Y; Liu YF; Chen YP; He DX; Yu CY
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S661-S670. PubMed ID: 30307317
[TBL] [Abstract][Full Text] [Related]
15. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
16. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
17. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
[TBL] [Abstract][Full Text] [Related]
18. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma.
Ji B; Cai H; Yang Y; Peng F; Song M; Sun K; Yan F; Liu Y
Acta Biomater; 2020 Jul; 111():363-372. PubMed ID: 32434082
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
Li Y; Wei J; Wei Y; Cheng L; Guo B; Meng F; Li F; Zhong Z
Biomacromolecules; 2020 Feb; 21(2):716-724. PubMed ID: 31809037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
